NotizieBenzingaReported Sunday, AbbVie’s SKYRIZI Shows Sustained Endoscopic Outcomes Through 144 Weeks In Crohn’s And 74.5% Fistula Resolution At Five Years, While RINVOQ Real-World Data Show Remission In Advanced Crohn’s Reported Sunday, AbbVie’s SKYRIZI Shows Sustained Endoscopic Outcomes Through 144 Weeks In Crohn’s And 74.5% Fistula Resolution At Five Years, While RINVOQ Real-World Data Show Remission In Advanced Crohn’s Benzinga 2026.10.12 07:03 (GMT+0) Apri Benzinga Altre notizie Newline by Fifth Third lancia carte Visa aziendali in oltre 40 paesi Cognizant amplia la partnership con Google Cloud con 18.000 ingegneri Alaska Airlines nomina Amaresh Siva come chief information officer TSX in calo: l’inflazione riaccende i timori sui tassi, petrolio in ritirata Il CEO di Teradyne Gregory Smith vende azioni per $1,36 milioni La direttrice di Teradyne Marilyn Matz vende azioni per $273.024
